Trametes versicolor Extract Modifies Human Fecal Microbiota Composition In vitro
Trametes versicolor is a mushroom used as a traditional Chinese medicine (Yun-zhi) for a wide array of seemingly disparate conditions. We hypothesized that many of its multiple purported activities could be mediated through stimulation of beneficial mutualist components of the microbiota. Human fecal microbiota was cultured anaerobically to determine its ability to ferment a common extract of T. versicolor, designated polysaccharide peptide (PSP), and the ability of PSP to alter the composition of the microbial community. The presence of PSP and fructooligosaccharides (FOS, a common prebiotic) in the medium, but not cellulose, significantly increased levels of Bifidobacterium spp. PSP also elevated Lactobacillus spp., while reducing Clostridium spp., Staphylococcus spp. and Enterococcus spp. Levels of Streptococcus spp., Bacteroides spp. and Escherichia did not significantly change. Fermentation of PSP increased the concentration of organic acids (lactate and short-chain fatty acids), decreased the pH, and induced β-galactosidase and β-glucosidase activities. The genera of the human microbiota that are promoted by FOS and other prebiotics are also stimulated by the Trametes versicolor extract, PSP. Thus, Trametes versicolor, a common East Asian botanical, contains putative prebiotic agents that alter human gut microbiota and pH. This prebiotic-like activity may help explain some of the plethora of the health benefits attributed to this traditional Chinese medicine.
KeywordsTrametes versicolor PSP Fecal microbiota In vitro fermentation
We thank Winsor Health Products, Ltd. for their gift of PSP and partial support, Dr. Gherman Wiederschain for helpful assistance with the manuscript, and the NIH for grants HD013021, HD059140, and AI075563.
Conflict of interest
Dr. Zhuoteng Yu declares that she has no conflict of interest. Dr. Bo Liu declares that he has no conflict of interest. Dr. Purna Mukherjee declares that she has no conflict of interest. Dr. David S. Newburg declares that he has no conflict of interest.
- 8.Hsieh TC, Wu JM (2001) Cell growth and gene modulatory activities of Yunzhi (Windsor Wunxi) from mushroom Trametes versicolor in androgen-dependent and androgen-insensitive human prostate cancer cells. Int J Oncol 18:81–88Google Scholar
- 9.Standish LJ, Wenner CA, Sweet ES et al (2008) Trametes versicolor mushroom immune therapy in breast cancer. J Soc Integr Oncol 6:122–128Google Scholar
- 10.Torkelson CJ, Sweet E, Martzen MR et al (2012) Phase 1 clinical trial of Trametes versicolor in women with breast cancer. ISRN Oncol 2012:251632Google Scholar
- 12.Harada H, Sakagami H, Konno K et al (1988) Induction of antimicrobial activity by antitumor substances from pine cone extract of Pinus parviflora Sieb. et Zucc. Anticancer Res 8:581–587Google Scholar
- 13.Su WJ, Waechter MJ, Bourlioux P et al (1987) Role of volatile fatty acids in colonization resistance to Clostridium difficile in gnotobiotic mice. Infect Immun 55:1686–1691Google Scholar
- 14.Reddy BS (1998) Prevention of colon cancer by pre- and probiotics: evidence from laboratory studies. Br J Nutr 80:S219–S223Google Scholar
- 16.Reddy BS (1999) Possible mechanisms by which pro- and prebiotics influence colon carcinogenesis and tumor growth. J Nutr 129:1478S–1482SGoogle Scholar